Ascendis Pharma A/S
ASND
311 hedge funds and large institutions have $17.8B invested in Ascendis Pharma A/S in 2026 Q2 according to their latest regulatory filings, with 90 funds opening new positions, 99 increasing their positions, 94 reducing their positions, and 51 closing their positions.
185% more call options, than puts
Call options by funds: $186M | Put options by funds: $65M
76% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 51
25% more capital invested
Capital invested by funds: $14.3B → $17.8B (+$3.52B)
14% more funds holding
Funds holding: 274 → 311 (+37)
6.7% more ownership
Funds ownership: 100.54% → 107.25% (+6.7%)
5% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 94
19% less funds holding in top 10
Funds holding in top 10: 16 → 13 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$362M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$138M |
| 3 |
State Street
Boston,
Massachusetts
|
+$99.7M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$77.1M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$45.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$139M |
| 2 |
NAMI
Nomura Asset Management International
Philadelphia,
Pennsylvania
|
-$127M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$95.3M |
| 4 |
PA
Perceptive Advisors
New York
|
-$85.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$77.3M |
ASND Hedge Fund Activity: Q2 2026 in Review
311 institutional investors reported a position in Ascendis Pharma A/S (ASND) for Q2 2026, worth a combined $17.8B — up 25% from $14.3B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new ASND positions and 51 closed out — a net gain of 39 holders — while 99 added to existing stakes and 94 trimmed.
The largest buyer was BlackRock, adding an estimated $362M. The largest seller was Artisan Partners, cutting an estimated $139M.
- 311 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2026, up from 274 in Q1 2026.
- Funds reported $17.8B of Ascendis Pharma A/S stock for Q2 2026, up 25% quarter-over-quarter.
- 90 funds opened new Ascendis Pharma A/S positions in Q2 2026 and 51 closed out, a net change of +39 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2026 was BlackRock, an estimated $362M added.
- The largest Ascendis Pharma A/S seller in Q2 2026 was Artisan Partners, an estimated $139M sold.
Based on aggregated 13F filings for Q2 2026.